retatrutide vs mazdutide

updated October 24, 2026

retatrutide (tier S) vs mazdutide (tier A): what each is, why each got its grade, half-life and source counts side by side.

retatrutide · tier S

the most potent weight loss drug ever tested. 24.2% in phase 2, then 28.3% in TRIUMPH-1 phase 3, 30.3% at two years. not approved yet.

tier rationale

now that the pivotal phase 3 obesity trial has read out (TRIUMPH-1: 28.3% weight loss at 12mg over 80 weeks, 30.3% at two years), reta has the strongest published obesity-drug efficacy in the catalog. Bariatric-surgery territory from a weekly shot. triple receptor mechanism adds glucagon agonism on top of tirz's dual mechanism, which pushes lipolysis and energy expenditure. S-tier based on phase 3 efficacy, but with meaningful open questions on safety and no announced approval date.

mazdutide · tier A

the GLP-1 + glucagon dual agonist approved in China. ~14% weight loss in GLORY-1 phase 3 at 48 weeks, ~20% at the higher dose. not FDA-approved.

tier rationale

mazdutide clears a high bar: a pivotal phase 3 obesity readout (GLORY-1, ~14% at 6 mg over 48 weeks; ~20% at 9 mg in the GLORY-2 program) and a 2025 NMPA approval in China for chronic weight management and type 2 diabetes. that is real efficacy with a real label behind it. it lands at A rather than S because the pivotal efficacy was generated in a single-ethnicity Chinese population and there is no US approval, only an active US phase 2 program. strong dual-agonist data, narrower geographic and regulatory reach than the FDA-approved incretins.

at a glance

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.